Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01227642 · ClinicalTrials.gov registry record · Phase 1

Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy

A Phase 1 study, sponsored by Beth Israel Medical Center.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target

NCT01227642: Completed Phase 1 study, sponsored by Beth Israel Medical Center.

NCT01227642 is a Phase 1 study that has completed, run by Beth Israel Medical Center. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01227642, a Phase 1 study, has completed, sponsored by Beth Israel Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target

Study Summary

In standard treatment, the seeds are placed throughout the prostate to treat the entire prostate. This is done because it was impossible to know where the cancer was located within the prostate. A new technique has been developed using the same ultrasound imaging that you probably had when you had your biopsy. Using this technique, areas likely to contain prostate cancer can be identified.In this early study of 15 subjects, we will test if this method to plan your prostate seed implant is safe and can be done as part of regular care. Areas identified as suspicious for cancer will be treated with higher doses of radiation while those areas not demonstrating cancer will be treated to the standard minimum dose. The higher dose areas will receive two times the minimum dose the prostate usually receives. Because this technique is not perfect, those areas not identified as cancerous should be treated in case there is a cancer area that the technique did not identify. Subjects enrolled in this study will then be followed with this ultrasound technique over the next two years to monitor the changes to the cancerous areas and will undergo a biopsy two years after the procedure. Subjects will, of course, be monitored to assess the success of the technique and its side effects.

Interventions

  • OTHER An ultrasound-based technique to identify prostate cancer
  • OTHER pre-implant transrectal ultrasound images and planning
  • OTHER ultrasound-based cancer-specific images

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2007-02
Est. Completion 2014-08
Phase Phase 1
Beth Israel Medical Center

44 total trials

What the finished NCT01227642 record still lists

NCT01227642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 3 interventions - of which An ultrasound-based technique to identify prostate cancer is the first listed.

NCT01227642 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01227642 about?

NCT01227642 is a clinical study titled "Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy". In standard treatment, the seeds are placed throughout the prostate to treat the entire prostate. This is done because it was impossible to know where the cancer was located within the prostate. A new technique has been developed using the same ultrasound imaging that you probably had when you had y...

What is the current status of trial NCT01227642?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2007-02. Estimated completion is 2014-08.

What interventions are being tested in trial NCT01227642?

The interventions under investigation include: An ultrasound-based technique to identify prostate cancer (OTHER), pre-implant transrectal ultrasound images and planning (OTHER), ultrasound-based cancer-specific images (OTHER).

Who is sponsoring clinical trial NCT01227642?

This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01227642's enrollment target sits among peer trials

14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01227642, the US trial registry maintained by the National Library of Medicine. NCT01227642 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.